Nova Mentis and Mycrodose Therapeutics have teamed up to test whether psychedelic treatments, such as Nova’s psilocybin — a potential behavioral therapy for fragile X syndrome — can be delivered via the skin using Mycrodose’s transdermal technology. The first studies assessing the diffusion of psychedelic compounds through the skin, called permeation studies, using Mycrodose’s technology, are underway. According to Mycrodose, its skin patch technology allows for a sustained and controlled delivery of small (micro) doses…

You must be logged in to read/download the full post.